Acrivon Therapeutics, Inc.
ACRVCIK 0001781174 · Pharmaceutical Preparations · Nasdaq
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$77.96M
+3.3% YoY
Q1 May 2026
EPS Diluted (TTM)
−$2.02
+15.1% YoY
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$69.43M
Q1 May 2026
Cash
$34.06M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
42.8M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.
Balance Sheet
Cash vs Debt
Latest news
All news →-
Moderate Neutral
Acrivon Therapeutics (ACRV) Adopts New Equity Plan
The company established an incentive stock plan authorizing up to 8.6 million shares for employee and director awards.